The Brominated Compound Aeroplysinin-1 Inhibits Proliferation and the Expression of Key Pro-Inflammatory Molecules in Human Endothelial and Monocyte Cells

Beatriz Martínez-Poveda¹,³, Javier A. García-Vilas¹,³, Casimiro Cárdenas¹, Esther Melgarejo¹, Ana R. Quesada¹,², Miguel A. Medina¹,²

¹Department of Molecular Biology and Biochemistry, Faculty of Sciences, University of Málaga, Málaga, Spain, ²CIBER de Enfermedades Raras (CIBERER), Málaga, Spain

Abstract

Aeroplysinin-1 is a brominated antibiotic used by some sponges for defense against bacterial pathogen invasion. Aeroplysinin-1 has a wide spectrum of anti-tumor action and behaves as a potent anti-angiogenic compound for bovine aortic endothelial cells. In this study, we demonstrate anti-angiogenic effects of aeroplysinin-1 on human endothelial cells. Furthermore, the response of angiogenesis related genes to aeroplysinin-1 treatment was studied in human endothelial cells by using gene arrays. The major changes were observed in thrombospondin 1 (TSP-1) and monocyte chemoattractant protein-1 (MCP-1), both of which were down-regulated. These inhibitory effects of aeroplysinin-1 were confirmed by using independent experimental approaches. To have a deeper insight on the anti-inflammatory effects of aeroplysinin-1 in endothelial cells, cytokine arrays were also used. This experimental approach confirmed effects on MCP-1 and TSP-1 and showed down-regulation of several other cytokines. Western blotting experiments confirmed down-regulation of ELTD1 (EGF, latrophilin and seven transmembrane domain-containing protein 1), interleukin 1α and matrix metalloproteinase 1 (MMP-1). These results along with our observation of a dramatic inhibitory effect of aeroplysinin-1 on cyclooxygenase-2 protein expression levels in endothelial cells and a human monocyte cell line suggest that aeroplysinin-1 could be a novel anti-inflammatory compound with potential pharmacological interest.

Introduction

Aeroplysinin-1 is an 1,2-dihydroarone-1,2-diol produced by Verongida sponges as a chemical defense activated after tissue injury to protect them from invasion of bacterial pathogens [1–4]. This compound can be obtained from sponges under controlled in vitro conditions and several analogues have been synthesized [5,6]. In addition to its antibiotic action [1,4,7], aeroplysinin-1 has been shown to have a wide spectrum of anti-tumor action [8–11]. Aeroplysinin-1 has been shown to display a strong anti-tumor effect on EGF-dependent tumor cell lines through its claimed inhibitory effect on the intrinsic protein tyrosine kinase activity of EGF-receptor kinase complex [9].

We have previously characterized aeroplysinin-1 as a potent anti-angiogenic compound in vitro and in vivo [12]. Most of the in vitro assays in that article were carried out with primary cultures of bovine aortic endothelial cells (BAEC). However, although BAEC are widely used as model cell cultures for angiogenesis research, some concerns have been raised due to the facts that they do not come from microvessels and they do not come from humans or model animals [13,14]. Therefore, a first objective of the present study was to test whether the results obtained in different in vitro angiogenesis-related assays are dependent on the origins of the endothelial cells. To fulfil this objective, we have made use of three types of human endothelial cells, namely, EVLC-2 (endothelial venous line cells), RF-24 (an immortalized line of HUVEC, human umbilical vein endothelial cells) and HMEC (immortalized human microvascular endothelial cells). Once demonstrated that our results are consistently reproduced in the three types of tested human endothelial cells, we used primary cultures of HUVEC to evaluate short-term effects of aeroplysinin-1 on angiogenesis-related genes expressed by human umbilical vein endothelial cells (HUVEC), by using commercial angiogenesis gene arrays and alternative validation procedures. Since results point to modulation of genes related with inflammation, we proceeded further by using a commercial cytokine array and alternative validation procedures. Furthermore, several key experiments were also carried out with the THP-1 human
monocyte cell line. In this case, results confirmed that monocyte cell proliferation was inhibited and the expression levels of cyclooxygenase-2 protein by these cells was decreased upon treatment with aeroplysinin-1. Altogether, the results shown here support a description of aeroplysinin-1 as an inhibitor of angiogenesis in human endothelial cells and as a new potent inhibitor of pro-inflammatory biomolecules.

**Results**

**Aeroplysinin-1 Treatment Inhibits Key Steps of Angiogenesis in Human Endothelial Cells**

In a previous report, we identified and characterized aeroplysinin-1 as a potent anti-angiogenic compound affecting several key steps of the process in BAEC [12]. Since that study was carried out using endothelial cells isolated from a great vessel (aorta) from no human source (cow), we began the present study trying to confirm the anti-angiogenic effects of aeroplysinin-1 in human endothelial cells from medium size vessels and microvessels.

Table 1 shows the IC$_{50}$ values determined in proliferation assays using MTT as described in Material and Methods. These values were in the low micromolar range, as it was the case of the published effect on BAEC proliferation [12].

The formation of a three-dimensional network of newly formed vessels is the final key event of the angiogenic process. *In vitro*, endothelial cells plated on Matrigel align themselves forming cords (Figure 1A, controls). Figure 1A (treatments) shows that treatment for 6 h with low micromolar concentrations of aeroplysinin-1 resulted in complete inhibition of endothelial cell alignment and cord formation for the three immortalized human endothelial cell lines tested. At lower concentrations of aeroplysinin-1 than those inducing complete inhibition of cord formation, partial inhibition could be observed in a dose-response manner, as shown in Figure 1A (histogram, below).

Matrix metalloproteinase-2 (MMP-2) is a key extracellular enzyme involved in basal membrane remodeling, a required step to allow for endothelial cell migration during active angiogenesis. Figure 1B shows that 2.5 μM aeroplysinin-1 induced a partial inhibition of MMP-2 in conditioned media from RF-24 and HMEC and an almost total inhibition of MMP-2 in conditioned media from EVLC-2.

For the rest of the study, we used either immortalized (RF-24) or primary cultures of HUVEC. Figure 1C (histogram, above) shows that 20 μM aeroplysinin-1 significantly inhibits RF-24 cell migratory potential after 7 h of treatment, as determined in a “wound healing” assay, under conditions not affecting cell viability (data not shown). However, this effect on migration was not detectable when we made use of a migration assay based on a transwell (Figure 1C, time-course curve, below). Figure 1D shows that 3–20 μM aeroplysinin-1 did not significantly affect the RF-24 cell invasive potential through a layer of Matrigel as determined by the invasion assay described in Material and Methods.

**Aeroplysinin-1 Treatment Induces Partial Inhibition of Two Angiogenesis Genes Related to Inflammation in HUVEC**

In order to evaluate short-term effects of aeroplysinin-1 on angiogenesis-related genes expressed by proliferating HUVEC, we used a human angiogenesis gene array. A typical result is shown in Figure 2A. Due to intrinsic variability of biological samples and the experimental procedure, we only took into account those changes in gene expression consistently repeated in five independent experiments. This stringent requirement was fulfilled by few genes. From them, two genes had the clearest changes upon aeroplysinin-1 treatment: thrombospondin 1 (TSP-1) and monocyte chemoattractant protein-1 (MCP-1). Aeroplysinin-1 (10 μM for 6 h) decreased the expression levels of TSP-1 protein and MCP-1 mRNA to 65±8% and 34±13% of their respective control values.

In this study, we confirmed our gene array results by using semi-quantitative RT-PCR for the MCP-1 mRNA expression levels (Figure 2B) and Western blotting for TSP-1 protein levels (Figure 2D). We could not detect a signal for MCP-1 protein in HUVEC by Western blotting due to a lack of sensitivity, but we could observe the inhibitory effect in the level of secreted MCP-1 to the medium by using a high sensitive ELISA assay: in samples of conditioned media from control HUVEC, there was 4.32±0.11 fg MCP-1/cell, whereas in conditioned media from HUVEC treated with aeroplysinin-1 (10 μM for 6 h) there was 2.30±0.41 fg MCP-1/cell (Figure 2C). That means that aeroplysinin-1 treatment decreased the levels of secreted MCP-1 by more than 45%. These additional results undoubtedly show that both MCP-1 mRNA and secreted protein and TSP-1 protein levels are decreased in samples from HUVEC treated with aeroplysinin-1 (10 μM for 6 h), as compared to control, untreated HUVEC.

**Aeroplysinin-1 Treatment Induces Partial Inhibition of the Secretion of Pro-Inflammatory Cytokines by HUVEC to Conditioned Media**

To further analyze the anti-inflammatory effects of aeroplysinin-1 in endothelial cells, we determined the cytokines expressed in conditioned media of primary cultures of both control and aeroplysinin-1-treated HUVEC with the Human Antibody L-series 507 Cytokine Array. Since the levels of inflammatory cytokines released from unstimulated HUVEC are low [15], in these experiments we made use of the SLIGKV-NH$_2$ peptide, which behaves as a mild inducer of inflammatory cytokine release from HUVEC [15]. Figure 3A shows a typical result. Due to intrinsic variability of biological samples and the experimental procedure, we only took into account those changes in cytokine levels consistently repeated in three independent experiments. Furthermore, only those changes greater than those corresponding to a factor 2 (that is, an increase of expression of at least the double, or an inhibition of the expression of at least 50%) were considered. These stringent requirements were only fulfilled by a few proteins (16), from which 9 (marked in Figure 3A) were further analyzed. Two of them (marked as cytokines 476 and 477 in the array) corresponded -according to supplier’s information- to thrombospondin and thrombospondin-1, respectively. That marked as protein 353 corresponded to MCP-1.

The other 6 proteins marked in Figure 3A were submitted to a validation test by using Western blotting. For two of these proteins, namely, those marked as proteins 265 (interleukin 9) and
low density lipoprotein receptor-related protein 6), Western blotting in our hands provided no signal and they were not further analyzed. Figures 3B and 3C show typical results obtained by Western blotting and the quantification of three independent experiments, respectively, for the rest of the marked proteins ELTD1, FADD, interleukin 1α and MMP-1.

The decrease in the levels of FADD detected in the array assays could not be confirmed by Western blotting. On the contrary, the effects on the other three proteins could be confirmed. In fact, as Figures 3B and 3C clearly show, aeroplysinin-1 treatment (10 μM for 16 h) of SLIGKV-NH₂ peptide-stimulated HUVEC produces decreases in the protein expression levels of ELTD1, MMP-1 and IL-1α in their conditioned media.

Aeroplysinin-1 Treatment Inhibits Cyclooxygenase-2 Expression in HUVEC

Since all the previous data clearly stressed the potential of the anti-angiogenic compound aeroplysinin-1 as an anti-inflammatory agent, we wanted to test whether it could down-regulate some other key pro-inflammatory gene not contained in the commercial arrays used. We decided to study COX-2, which is overexpressed in many tumors and plays a key role in atherosclerosis [16–18]. Constitutive expression of COX-2 is undetectable in HUVEC. However, COX-2 messenger and protein expression levels in HUVEC are easily induced by phorbol myristate acetate (PMA). Quantitative RT-PCR assay shows that aeroplysinin-1 treatment (10 μM for 4.5 h) decreased the expression levels of PMA (50 ng/
mL)-induced COX-2 mRNA by more than 70% (Figure 4A). On the other hand, Western blot assays show that aeroplysinin-1 treatment (10 μM for 4.5 h) completely inhibited PMA-induced expression of endothelial cell COX-2 protein (Figure 4B). Therefore, aeroplysinin-1 seems to have inhibitory effects on PMA-induced expression of COX-2 protein that may involve effects at the transcriptional and post-transcriptional levels. The effect of aeroplysinin-1 on COX-2 protein expression levels was also shown in experiments with cycloheximide (90 μg/mL) pretreatment for 1 h (Figures 4C and D).

Aeroplysinin-1 Treatment Inhibits Key Processes and Decreases the Expression Levels of Key Biomolecules in Human Pro-Inflammatory THP-1 Monocytes

Due to the clear inhibitory effect of aeroplysinin-1 on pro-inflammatory biomolecules, we wanted to test the effects of this compound on pro-inflammatory cells. Figure 5 shows that, in fact, aeroplysinin-1 inhibits processes and molecules in THP-1 human pro-inflammatory monocytes. Figure 5A shows that aeroplysinin-1 inhibits THP-1 cell proliferation in a dose-response manner with the IC_{50} value in the micromolar range (24.6 ± 1.0 μM). Figure 5B shows that both MCP-1 and COX-2 mRNA expression levels are significantly reduced with 10 μM aeroplysinin-1 treatment. In contrast, 10 μM aeroplysinin-1 treatment seemed to increase the expression levels of TSP-1 (Figure 5B). Figure 5C shows that the decrease in the expression of COX-2 is also detectable in the protein levels, as shown in Western blot. On the other hand, Figures 5D and E show that aeroplysinin-1 treatment in the 3-20 μM concentration range does not affect migration and invasion capabilities of THP-1 cells.

**Discussion**

Our group demonstrated unambiguously that aeroplysinin-1, a brominated compound produced by marine sponges as a mechanism of defense [3,4], is a potent natural inhibitor of angiogenesis [12]. In that study, most of the in vitro experiments were carried out using bovine aorta endothelial cells (BAEC). As mentioned in the Introduction, BAEC are very frequently used as model cell cultures for angiogenesis research, but some concerns have been raised due to the facts that they do not come from microvessels and they do not come from humans or model animals [13,14]. In the first part of the present study, our aim was to test whether the in vitro effects of aeroplysinin-1 we observed in BAEC could be reproduced in human endothelial cells obtained from blood vessels with different sizes. The results obtained in the present study clearly reproduced the inhibitory effects of aeroplysinin-1 on endothelial cell proliferation, differentiation and MMP-2 expression (Table 1 and Figure 1) in the same range of micromolar concentrations previously used in BAEC [12] and in studies describing the anti-angiogenic effect of other natural compounds [19,20]. Only the described slight inhibitory effect of aeroplysinin-1 in the invasion assay when we used BAEC [12] could not be reproduced in the human endothelial cells tested in the present study (Figure 1D). On the other hand, the set of results involving endothelial cell proliferation, differentiation and MMP-2 expression were consistently reproduced in the different human endothelial cells tested, irrespective of their origins. These results give support to the claim that any of these human endothelial cell types can be a useful and valuable model for in vitro angiogenesis research.

In our previously published work describing aeroplysinin-1 as a potent anti-angiogenic compound, we identified two molecular targets for its effects, namely, MMP-2 and urokinase [12]. The
Present study confirms MMP-2 as a molecular target of aeroplysinin-1 (Figure 1B).

A second experimental approach to get more information on potential new molecular targets of aeroplysinin-1 has been the use of commercial low-density arrays of genes related with angiogenesis. In many published articles, authors make only an array experiment or a duplicate experiment, and in only a few published articles these experiments are independently repeated three or more times. Nonetheless, in the present study we only selected those modulatory effects that consistently were repeated in the whole set of five independent experiments. Among those genes fulfilling this strong requirement, the only two ones with decreases higher than 25% in their expression levels were TSP-1 and MCP-1. Gene expression results obtained with gene arrays should be validated by using alternative, independent experimental approaches. Our results in the array experiments were confirmed by different, independent experimental approaches (Figure 2) showing that aeroplysinin-1 treatment down-regulates TSP-1 and MCP-1, two gene products involved in angiogenesis and also related to inflammation. TSP-1 has been described as an...
endogenous anti-angiogenic compound. However, TSP-1 is multifunctional, playing different biological activities in different cell types [21]. In fact, TSP-1 is one of the major proteins released from activated platelets [22]. Furthermore, TSP-1 expression is up-regulated in inflammation and inflammation-dependent pathologies, including atherosclerosis and coronary artery disease [22–24]. Very recently, it has been suggested that some of the pathophysiological connections of TSP-1 expression might be through its function as a hub in a mechanism for autocrine regulation of T cell adhesion and migration [24]. On the other hand, MCP-1 is a member of the C-C class of the beta chemokine family with inflammatory properties [25]. MCP-1 up-regulation is related to macrophage recruitment, angiogenesis and survival in human breast cancer [26]. In addition, MCP-1 plays a critical role in the recruitment and activation of monocytes and in the development of atherosclerosis [27]. We have recently shown that another anti-angiogenic natural compound (namely, epigallocatechin 3-gallate) exerts a potent inhibitory effect on MCP-1 in inflammatory cells [28,29]. In conclusion, the extreme selectivity of the conditions established in our experimental setup has been essential to identify two true positives as new molecular targets for the biological effects of aeroplysinin-1. Furthermore, since these are key regulators of inflammation, these results were essential for our decision to devote the last part of the present study to test further the potential of aeroplysinin-1 as a negative modulator of pro-inflammatory biomolecules.

Since both MCP-1 and TSP-1 are pro-inflammatory molecules, data shown in Figure 2 clearly indicated that aeroplysinin-1 behaves as a potent anti-inflammatory agent. To get a deeper insight on the anti-inflammatory effects of aeroplysinin-1 in endothelial cells, we decided to use the Human Antibody L-series 507 Cytokine Arrays, which allows for the simultaneous semi-quantitative determination of 507 cytokines in conditioned media of cultured cells. Since the levels of inflammatory cytokines released from unstimulated HUVEC are low [15], in these experiments we made use of the SLIGKV-NH₂ peptide, a selective agonist of the proteinase-activated receptor-2 (PAR2) [30,31] that behaves as a mild inducer of inflammatory cytokine release from HUVEC [15].

Expression results obtained with this kind of arrays should be validated by using alternative, independent experimental approaches. This array assay is an additional and independent experimental approach that validates the original observation of the inhibitory effect of aeroplysinin-1 on both TSP-1 and MCP-1 (cytokines 476, 477 and 353 in Figure 3A) expression by HUVEC. Other three new molecular targets of aeroplysinin-1 were selected with the cytokine array assay and confirmed with independent experimental approaches (Figure 3). ELTD1 (EGF, latrophilin and seven transmembrane domain-containing protein 1) is a poorly characterized protein belonging to the secretin family of G-protein-couple peptide hormone receptors that has been previously documented as expressed in heart, lung and vessels [32].
Little is known concerning its functions, although it has been shown to be developmentally regulated in the heart, to be associated with tick burden in cattle, and to be one of eight neuronal genes responsible for subcutaneous fat thickness [32–34]. The matrix metalloproteinase-1 (MMP-1), also known as interstitial collagenase, is the only enzyme able to initiate the breakdown of the interstitial collagens (types I, II and III). MMP-1 is involved in the pathogenesis of inflammatory diseases and is upregulated by inflammation [35–37]. Finally, interleukin 1α has been described to play a key role in inflammatory and immune responses [38–41]. It is important to take these results related with cytokines with caution since, under the conditions used, an effect of aeroplysinin-1 on PAR-2 signaling cannot be ruled out.

Since these results clearly stressed that the anti-angiogenic compound aeroplysinin-1 could also be a potential anti-inflammatory agent, we wanted to test whether it could down-regulate some other key pro-inflammatory gene not contained in the commercial arrays used. We decided to study COX-2, which is overexpressed in many tumors and plays a key role in atherosclerosis [16–18]. Our results clearly show that aeroplysinin-1 completely abrogates the PMA-induced expression of COX-2 protein with a partial effect on the expression levels of COX-
2 mRNA (Figure 4A and B). We could find that pre-treatment with CHX was not able to preclude PMA induction of COX-2 protein expression after 4.5 h of treatment (Figure 4C and D).

However, the inhibitory effect of aeroplysinin-1 on this induction was smaller (Figure 4C and D) than that observed on cells not pretreated with CHX (Figure 4B). These data seem to indicate that aeroplysinin-1 could have effects not only on the expression of COX-2 but also on its stability. These results are not conclusive and more experimental effort should be required to address this issue.

Finally, we have studied some of the effects that aeroplysinin-1 treatment can induce in human THP-1 pro-inflammatory monocytes. In fact, we have shown that aeroplysinin-1 inhibits THP-1 cell proliferation in a dose-response manner, although the IC50 value is achieved at 8-fold concentrations those required for getting a 50% of inhibition of human endothelial cell proliferation under the assay conditions used in the present study (Figure 5A). We have previously shown that these pro-inflammatory cells are also targets for other anti-angiogenic compounds [29]. Further studies on the effects of aeroplysinin-1 on THP-1 cells shown in the present study (Figure 5A).

In conclusion, the results of this study confirm that aeroplysinin-1 inhibits human endothelial cell angiogenesis and suggest that aeroplysinin-1 could be a novel potential anti-inflammatory compound. These results open new ways to the potential pharmacological action of aeroplysinin-1 not only on angiogenesis and cancer [8–12], but also on atherosclerosis and inflammation-dependent diseases. Undoubtedly, this suggestion deserves to be studied in the near future.

Materials and Methods

Ethics Statement

Primary cultures of HUVEC were obtained from umbilical cords donated at the Maternity of the University Clinical Hospital (Málaga) with the verbal informed consent of donors according to the procedure approved by the ethics committee. All personal data were maintained anonymous and the whole procedure remained anonymous to the authors of this article, who received the donated umbilical cords outside of the operating room. All the procedures were carried out following the rules provided by the bioethical committee of the University of Málaga. This study is part of a research project approved by the bioethical committee of the University of Málaga.

Chemicals and Reagents

Aeroplysinin-1 was provided by Instituto Biomar (León, Spain) and was dissolved in DMSO and stored at -20°C. Mouse anti-Cox-2 antibody was purchased from Santa Cruz Biotechnology and diluted 1:1000 in TBS-T containing 1% BSA and 0.02% sodium azide. Mouse anti-TSP-1 antibody was purchased from Neomarkers and diluted 1:1000 in TBS-T containing 5% non-fat dry milk. The rest of the antibodies used in this study were provided by Abcam. All other reagents, including the peptide SLIGKV-NH₂, were supplied by Sigma-Aldrich.

Cell Culture

The three immortalized human endothelial cell lines were kindly supplied by Dr. Arjan W. Griffioen (Maastricht University, Netherlands), who previously characterized them elsewhere [42]. They were grown in RPMI-1640 medium supplemented with glutamine (2 mM), penicillin (50 IU/mL), streptomycin (50 mg/l), amphotericin (1.25 mg/L), 10% fetal bovine serum and 10% human serum. Primary cultures of human umbilical vein endothelial cells (HUVEC) were isolated from umbilical cords by collagenase digestion [43] and cultured as described elsewhere [12]. U937 and THP-1 human inflammatory (monocytes) cells were supplied by ATCC and maintained as recommended by the supplier.

In vitro Angiogenesis Assays

All the in vitro angiogenesis assays used in this work have been extensively described by us elsewhere [12–19]. For the MTT proliferation assay, endothelial cells (2.5×10⁵ cells in a total volume of 100 μL of complete medium) were incubated in each well with serial dilutions of aeroplysinin-1. After 3 days of incubation in the dark (37°C, 5% CO2 in a humid atmosphere), 10 μL of MTT (5 mg/mL in PBS) was added to each well and the plate was incubated for further 4 h (37°C). The resulting formazan was dissolved in 150 μL of 0.04 N HCl-2 propanol and read at 550 nm. All determinations were carried out in quadruplicate and at least three independent experiments were carried out. IC50 values were calculated as those concentrations of compound yielding 50% cell survival, taking the values obtained for control as 100%.

The rest of the in vitro assays used in this study were carried out under conditions [aeroplysinin-1 concentrations and duration of treatments] that did produce no cytotoxic effect on cells, as determined by modified MTT survival assays.

Table 2. Primers, amplicon sizes and qPCR conditions.

| Gene       | Primers                                      | Amplicon size | Number of cycles | PCR conditions               |
|------------|----------------------------------------------|---------------|-----------------|------------------------------|
| MCP-1      | Forward 5'-GCC TTA AGT AAT GTT AAT TCT TAT  | 241 bp        | 40              | IC50 value is achieved at 8-fold concentrations those required for getting a 50% of inhibition of human endothelial cell proliferation under the assay conditions used in the present study (Figure 5A). We have previously shown that these pro-inflammatory cells are also targets for other anti-angiogenic compounds [29]. Further studies on the effects of aeroplysinin-1 on THP-1 cells shown in the present study (Figure 5A). | Pretreatment can induce in human THP-1 pro-inflammatory monocytes. In fact, we have shown that aeroplysinin-1 inhibits THP-1 cell proliferation in a dose-response manner, although the IC50 value is achieved at 8-fold concentrations those required for getting a 50% of inhibition of human endothelial cell proliferation under the assay conditions used in the present study (Figure 5A). We have previously shown that these pro-inflammatory cells are also targets for other anti-angiogenic compounds [29]. Further studies on the effects of aeroplysinin-1 on THP-1 cells shown in the present study (Figure 5A). |
| COX-2      | Forward 5'-CTG TAT CCC GCC CTG CTG GTG      | 282 bp        | 40              | IC50 value is achieved at 8-fold concentrations those required for getting a 50% of inhibition of human endothelial cell proliferation under the assay conditions used in the present study (Figure 5A). We have previously shown that these pro-inflammatory cells are also targets for other anti-angiogenic compounds [29]. Further studies on the effects of aeroplysinin-1 on THP-1 cells shown in the present study (Figure 5A). |
| TSP-1      | Forward 5'-TGG TCT TGG GAA CCC AAC CA       | 187 bp        | 40              | IC50 value is achieved at 8-fold concentrations those required for getting a 50% of inhibition of human endothelial cell proliferation under the assay conditions used in the present study (Figure 5A). We have previously shown that these pro-inflammatory cells are also targets for other anti-angiogenic compounds [29]. Further studies on the effects of aeroplysinin-1 on THP-1 cells shown in the present study (Figure 5A). |
| GAPDH      | Forward 5'-GCC AAG TTC AAG GCC ACA AT       | 157 bp        | 40              | IC50 value is achieved at 8-fold concentrations those required for getting a 50% of inhibition of human endothelial cell proliferation under the assay conditions used in the present study (Figure 5A). We have previously shown that these pro-inflammatory cells are also targets for other anti-angiogenic compounds [29]. Further studies on the effects of aeroplysinin-1 on THP-1 cells shown in the present study (Figure 5A). |

doi:10.1371/journal.pone.0055203.t002
In the assay for tube formation on Matrigel by endothelial cells, Matrigel (50 μL of about 10.5 mg/mL) at 4°C was used to coat each well of a 96-well plate and allowed to polymerize at 37°C for a minimum of 30 min. 5 × 10^4 cells were added with 200 μL of medium. Finally, different amounts of aeroplysinin-1 were added and incubated at 37°C in a humidified chamber with 5% CO₂ for 6 h. After incubation, cultures were observed and photographed with a NIKON inverted microscope DIAPHOT-TMD (NIKON Corp., Tokyo, Japan). Each concentration was tested in triplicate.

“Tubular” structures were counted using the NIH Image 1.6 software.

MMP-2 expression of control and treated human immortalized HUVEC was analyzed by gelatin zymography as previously described by us [19]. The migratory activity of endothelial cells was assessed using a “wound-healing” migration assay. Confluent monolayers in 6-well plates were “wounded” with pipet tips. After washing, cells were supplied with 1.5 mL complete medium in the absence (controls) or presence of different concentrations of aeroplysinin-1. Wounded areas were photographed at different times of incubation. An additional assay of migration is that using a modified Boyden chamber. Migration of fluorescence-labeled endothelial cells was assayed by using a 24-well fluorescence-opaque membrane insert. This assay allows monitoring of the process in real time, because it eliminates the need to remove nonmigratory cells before quantification of migratory cells. Cells were labeled in situ with 5 μg/mL Calcein-AM in complete culture medium for 2 h at 37°C. Cells were added to 8 μm FALCON HTS FluoroBlok inserts (Becton Dickinson) at a density of 5 × 10^4 cells/insert in the absence or the presence of the indicated concentrations of aeroplysinin-1. Complete culture medium with FBS was used as a chemoattractant in the lower wells. The inserts were incubated at 37°C, and the real-time kinetics of cell migration was determined by taking readings at the indicated time points. Fluorescence of cells that had migrated through the inserts was measured via the Fluorescence Microplate Reader (FL600FA, BIO-TEK Instruments, Winooski, VT) in the bottom-read mode, with excitation/emission wavelengths of 485/530 nm and a gain setting of 75. The number of cells that migrated through the insert was calculated by interpolation via a standard curve comparing relative fluorescence units with the cell number.

The invasion assay was performed in the absence of any chemoattractant. Hence, HUVEC were treated with 10 μM aeroplysinin-1 for 4.5 h. Control, untreated HUVEC were incubated in fresh culture medium supplemented with 100 μM SLIGKV-NH₂ peptide in the absence of serum for 16 h. Afterwards, conditioned media were collected. Human Antibody L-series 507 Cytokine Arrays (Ray-Biotech) were used to analyse cytokine levels in HUVEC conditioned media following supplier’s instructions.

Quantitative RT-PCR

For quantitative RT-PCR (qPCR), total RNA isolation and complementary DNA synthesis were performed as described above and PCR reactions were done using KAPA SYBR Fast Master Mix (2x) Universal (KAPA Biosystems) in a Eco™ Real-Time PCR System. qPCR was performed in triplicate for each sample according to the manufacturer’s instructions. All qPCR data were normalized to GAPDH expression. Primers, amplicon size, number of cycles and qPCR conditions for each gene are shown in Table 2.

Western Blotting

For Western blotting, treated and control cells were lysed in Laemmli’s loading buffer 2X and boiled for 5 min at 95°C; samples were separated in a SDS-PAGE electrophoresis and blotted onto a nitrocellulose membrane. After blocking in TBS-T plus 5% w/v dry non-fat milk, membranes were probed with primary antibodies overnight at 4°C. Membranes were washed in TBS-T and probed with secondary antibody linked to horseradish peroxidase for 1 hour at room temperature. After washing, membranes were developed using the ECLTM system (Amersham Biosciences) or the SuperSignal West Fico Chemiluminiscent Substrate system (Thermo). For validation of relevant movements in cytokine array assays, Western blotting was carried out exactly as indicated in the instructions for users of this array.

Determination of MCP-1 Secretion to HUVEC Culture Supernatants

MCP-1 protein in HUVEC culture supernatants after the treatment with aeroplysinin-1 was measured using a commercial MCP-1 Human Biotrak Easy ELISA kit (GE Healthcare) according to the manufacturers instructions. The absorbance at 450 nm was determined using a microplate reader 680 (Bio-Rad). The MCP-1 protein levels in the conditioned medium were carried out in four independent cultures.

Statistical Analysis

For all the assays, at least three independent experiments were carried out. Results are expressed as mean ± S.D. Statistical significance was determined by the Students paired sample test. Values of p<0.05 were considered to be significant.

Acknowledgments

Authors are indebted to Auxiliadora López Jiménez for her excellent technical assistance. Thanks are due to Instituto Biomar S.A. (León, Spain) for providing us the compound. Thanks are due to Dr. Arjan W. Griffioen (Maastricht University, Netherlands) for kindly providing us the three immortalized human endothelial cell lines used in the present study.

Author Contributions

Conceived and designed the experiments: ARQ MAM. Performed the experiments: BMP JAGV CC EM. Analyzed the data: BMP JAGV ARQ MAM. Wrote the paper: ARQ MAM.
References

1. Fattorusso E, Minali L, Sodano G (1972) Aeroplysinin-1, an antibacterial bromo-compound from the sponge Verongia aerophoba. J Chem Soc Perkin 1: 15–19.

2. Debitus C, Guella G, Mancini II, Waikedre J, Guemas JP, et al. (1998) Quinolones from a bacterium and tyrosine metabolites from its host sponge, Suberea creba from the Coral Sea. J Mar Biotechnol 6: 136–141.

3. Thomes C, Wolff M, Padmakumar K, Ebel R, Proksch P (2004) Chemical defense of Mediterranean sponges Aplysina cavernicola and Aplysina aerophoba. Z Naturforsch C 59: 113–122.

4. Thomes C, Ebel R, Proksch P (2006) Activated chemical defense in aphyllos sponge species. J Chem Ecol 32: 97–123.

5. Nieder M, Hager L (1985) Conversion of alpha-amino acids and peptides to nitriles and aldehydes by bromoperoxidase. Arch Biochem Biophys 240: 121–127.

6. Hinterding K, Knebel A, Herrlich P, Waldmann H (1998) Synthesis and bioactive evaluation of aeroplysinin analogues: a new class of receptor tyrosine kinase inhibitors. Bioorg Med Chem 6: 1153–1162.

7. Teeyapant A, Woerdenbag HJ, Kreis P, Hacker J, Wray V, et al. (1993) Antibiotic and cytotoxic activity of brominated compounds from the marine sponge Verongia aerophoba. Z Naturforsch C 48: 939–943.

8. Kreuter MH, Bernd A, Holzmann H, Muller-Klieser W, Maizaidofo A, et al. (1989) Cytostatic activity of aeroplysinin-1 against lymphoma and epitheloma cells. Z Naturforsch C 44: 680–681.

9. Kreuter MH, Leske RE, Rinaldi F, Muller-Klieser W, Maizaidofo A, et al. (1990) Inhibition of intrinsic protein tyrosine kinase activity of EGF-receptor kinase complex from human breast cancer cells by the marine sponge metabolite (α)-aeroplysinin-1. Comp Biochem Physiol B 97: 131–138.

10. Kreuter MH, Robitski A, Chang S, Steffen R, Michaelis M, et al. (1992) Production of the cytostatic agent aeroplysinin by the sponge Verongia aerophoba in in vitro culture. Comp Biochem Physiol C 101: 103–187.

11. Koulman A, Proksch P, Ebel R, Beekman AC, van Uden W, et al. (1996) Anti-angiogenic and anti-inflammatory activities of aeroplysinin-1, a brominated sponge alkaloid from the sponge Aplysina aerophoba. J Nat Prod 59: 591–594.

12. Rodriguez-Neto S, Gonzalez-Iriarte M, Carmona R, Muotz-Chapuli R, Medina MA, et al. (2002) Antiangiogenic activity of aeroplysinin-1, a brominated compound isolated from a marine sponge. FASEB J 16: 261–263.

13. Anandarbuch R, Lewis R, Shinners B, Kubai L, Akhtar N (2003) Angiogenesis assays: a critical overview. Clin Chem 49: 32–40.

14. Staton CA, Reed MW, Brown NJ (2009) LOX-1 inhibition in myocardial ischemia-reperfusion injury: modulation of MMP-1 and inflammation. Am J Physiol Heart Circ Physiol 295: H1795–1801.

15. Ray A, Shakya A, Ray BK (2005) Inflammation-responsive transcription factors. Curr Med Chem Cardiovasc Hematol Agents 1: 50–56.

16. Li D, Williams V, Liu L, Chen H, Sawamura T, et al. (2002) LOX-1 inhibition in myocardial ischemia-reperfusion injury: modulation of MMP-1 and inflammation. Am J Physiol Heart Circ Physiol 283: H1795–1801.

17. Li D, Williams V, Liu L, Chen H, Sawamura T, et al. (2001) Inflammation in stasis dermatitis upregulates MMP-1, MMP-2 and MMP-13 expression. J Dermatol Sci 25: 198–205.

18. Lee KT, Byun MJ, Kang KS, Park EW, Lee SH, et al. (2011) Neuronal genes for subcutaneous fat thickness in human and pig are identified by local genomic sequencing and combined SNP association study. PLoS One 6: 1–10.

19. Lee FY, Lockinser MF, Fischer SM (1994) Interleukin-1 alpha mediates phorbol ester-induced inflammation and epidermal hyperplasia. FASEB J 8: 1081–1087.

20. Chapman PT, Yavvood H, Harrison AA, Stocker CJ, Jamar F, et al. (1997) Endothelial activation in monosodium urate monohydrate crystal-induced inflammation: in vitro and in vivo studies on the roles of tumor necrosis factor alpha and interleukin-1. Arthritis Rheum 40: 955–965.

21. Maes M, Vtwis FN, Kubera M, Ringel K (2011) Evidence for inflammation and activation of cell-mediated immunity in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). Increased interleukin-1, tumor necrosis factor-alpha, PMN-elastase, lysozyme and neopterin. J Affect Disord.

22. de Vrije TJ, van der Linden E, Griffioen AW (2008) Angiogenic profiling of tumor cells on Matrigel in in vitro culture. Comp Biochem Physiol C 101: 183–187.

23. Zhou X, Huang J, Shen J, Zhao J, Ge D, et al. (2004) Genetic association analysis of myocardial infarction with thromboponin-1 N700S variant in a Chinese population. Thromb Res 113: 181–186.

24. Forsow A, Liu Z, Sundqvist KG (2007) Receptor communication within the lymphocyte plasma membrane: a role for the thromboponin family of matrixcellular proteins. Cell Mol Life Sci 64: 66–76.

25. Conti P, DiGiacchino M (2000) MCP-1 and RANTES are mediators of acute and chronic inflammation. Allergy Asthma Proc 22: 133–137.

26. Yu JL, Rkl JW (2003) Host microenvironment in breast cancer development: inflammatory and immune cells in tumour angiogenesis and arteriogenesis. Breast Cancer Res 5: 83–88.

27. Berda U, Matsui K, Murakami Y, Shimada K (2002) Monocye chemotactract protein-1 and coronary artery disease. Clin Cardio 25: 143–147.

28. Melgarejo E, Medina MA, Sanchez-Jimenez F, Botana LM, Dominguez M, et al. (2007) (-)-Epigallocatechin-3-gallate interacts with cell adhesiveness, migration and its potential to recruit monocytes. Cell Mol Life Sci 64: 2690–2701.

29. Melgarejo E, Medina MA, Sanchez-Jimenez F, Urdiales JL (2009) Epigallococatechin gallate reduces human monocyte mobility and adhesion in vitro. Br J Pharmacol 153: 1705–1712.

30. Scarborough RM (2003) Protease-activated receptor-2 antagonists and agonists. Curr Med Chem Cardiovasc Hematol Agents 1: 73–82.

31. Ososkovaya VS, Bumett NW (2004) Protease-activated receptors: contribution to physiology and disease. Phys Rev 84: 579–621.

32. Nechiporuk T, Urness LD, Keating MT (2001) ET-1, a novel seven-transmembrane receptor that is developmentally regulated in the heart. ET-1 is a member of the secretin family and belongs to the epidermal growth factor-seven-transmembrane subfamily. J Biol Chem 276: 4150–4157.

33. Porto Neto LR, Bunch RJ, Barreras N (2001) DNA variation in the gene ETLD1 is associated with tuck burden in cattle. Anim Genet 42: 50–55.

34. Lee FY, Lockinser MF, Fischer SM (1994) Interleukin-1 alpha mediates phorbol ester-induced inflammation and epidermal hyperplasia. FASEB J 8: 1081–1087.

35. de Vrije TJ, van der Linden E, Griffioen AW (2008) Angiogenic profiling and comparison of immortalized endothelial cells for functional genomics. Exp Cell Res 314: 264–272.

36. Kubota Y, Kleinman HK, Martin GR, Lawley TJ (1988) Role of laminin and basement membrane in the morphological differentiation of human endothelial cells into capillary-like structures. J Cell Biol 107: 1589–1598.